| Trial ID: | L4930 |
| Source ID: | NCT04246190
|
| Associated Drug: |
Ckd-501 And D759
|
| Title: |
A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type2 Diabetes Mellitus
|
| Interventions: |
DRUG: CKD-501 and D759|DRUG: CKD-396
|
| Outcome Measures: |
Primary: Cmax of CKD-501, D759 and CKD-396, Maximum plasma concentration of CKD-501, D759 and CKD-396, 0(predose)~48 hours|AUClast of CKD-501, D759 and CKD-396, Area under the plasma concentration-time curve to last concentration of CKD-501, D759 and CKD-396, 0(predose)~48 hours |
|
| Sponsor/Collaborators: |
Sponsor: Chong Kun Dang Pharmaceutical
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
26
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2020-02-24
|
| Completion Date: |
2020-07-16
|
| Results First Posted: |
|
| Last Update Posted: |
2020-02-05
|
| Locations: |
Yonsei University Severance Hospital, Soeul, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT04246190
|
